The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Romuald Girard and Issam Awad.
Romuald Girard
Connection Strength
9.247
Issam Awad
  1. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 02 16; 88(3):686-697.
    View in: PubMed
    Score: 0.783
  2. Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. 2018 02; 9(1):34-43.
    View in: PubMed
    Score: 0.614
  3. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. J Neurosurg. 2017 Jul; 127(1):102-110.
    View in: PubMed
    Score: 0.572
  4. Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease. J Neurosci Methods. 2016 09 15; 271:14-24.
    View in: PubMed
    Score: 0.567
  5. Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016; 10(3):255-64.
    View in: PubMed
    Score: 0.553
  6. Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations. Transl Stroke Res. 2024 Jul 09.
    View in: PubMed
    Score: 0.247
  7. Transcriptomic signatures of individual cell types in cerebral cavernous malformation. Cell Commun Signal. 2024 01 09; 22(1):23.
    View in: PubMed
    Score: 0.239
  8. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling. Stroke. 2024 01; 55(1):31-39.
    View in: PubMed
    Score: 0.238
  9. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome. Stroke. 2024 01; 55(1):22-30.
    View in: PubMed
    Score: 0.238
  10. Corrigendum to "Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu" [J. Autoimmun. 113 (2020) 102469]. J Autoimmun. 2023 Nov; 140:103116.
    View in: PubMed
    Score: 0.234
  11. Inflammatory Mechanisms in a Neurovascular Disease: Cerebral Cavernous Malformation. Brain Sci. 2023 Sep 17; 13(9).
    View in: PubMed
    Score: 0.234
  12. Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling. medRxiv. 2023 Jun 05.
    View in: PubMed
    Score: 0.229
  13. Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation. J Stroke Cerebrovasc Dis. 2023 Jul; 32(7):107167.
    View in: PubMed
    Score: 0.228
  14. Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans. ACS Pharmacol Transl Sci. 2022 May 13; 5(5):266-277.
    View in: PubMed
    Score: 0.212
  15. Propranolol as therapy for cerebral cavernous malformations: a cautionary note. J Transl Med. 2022 04 05; 20(1):160.
    View in: PubMed
    Score: 0.212
  16. Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 10 01; 131(19).
    View in: PubMed
    Score: 0.204
  17. COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. J Stroke Cerebrovasc Dis. 2021 Nov; 30(11):106101.
    View in: PubMed
    Score: 0.203
  18. Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 02 01; 131(3).
    View in: PubMed
    Score: 0.195
  19. Biomarkers of cavernous angioma with symptomatic hemorrhage. JCI Insight. 2019 06 20; 4(12).
    View in: PubMed
    Score: 0.174
  20. Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery. 2019 06 01; 84(6):1157-1168.
    View in: PubMed
    Score: 0.174
  21. Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes. JCI Insight. 2019 Feb 07; 4(3).
    View in: PubMed
    Score: 0.170
  22. Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III): A Posthoc Root-Cause Analysis. Neurosurgery. 2018 12 01; 83(6):1260-1268.
    View in: PubMed
    Score: 0.168
  23. Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. 2018 06 08; 122(12):1716-1721.
    View in: PubMed
    Score: 0.161
  24. Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial. Neurosurgery. 2017 Nov 01; 81(5):860-866.
    View in: PubMed
    Score: 0.156
  25. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. J Magn Reson Imaging. 2018 04; 47(4):1133-1138.
    View in: PubMed
    Score: 0.153
  26. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194.
    View in: PubMed
    Score: 0.146
  27. B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models. J Neuroimmune Pharmacol. 2016 06; 11(2):369-77.
    View in: PubMed
    Score: 0.140
  28. Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. AJNR Am J Neuroradiol. 2016 Jul; 37(7):1209-15.
    View in: PubMed
    Score: 0.139
  29. Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2015 Oct; 35(10):1632-9.
    View in: PubMed
    Score: 0.131
  30. Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 Signaling. Arterioscler Thromb Vasc Biol. 2024 Jun; 44(6):1246-1264.
    View in: PubMed
    Score: 0.061
  31. Pathologic features of brain hemorrhage after radiation treatment: case series with somatic mutation analysis. J Stroke Cerebrovasc Dis. 2024 Jul; 33(7):107699.
    View in: PubMed
    Score: 0.061
  32. Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations. Nat Commun. 2023 11 02; 14(1):7009.
    View in: PubMed
    Score: 0.059
  33. Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Commun Med (Lond). 2023 Mar 03; 3(1):35.
    View in: PubMed
    Score: 0.056
  34. Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Transl Stroke Res. 2023 08; 14(4):513-529.
    View in: PubMed
    Score: 0.054
  35. Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. Circ Res. 2022 04 15; 130(8):1204-1229.
    View in: PubMed
    Score: 0.053
  36. Developmental venous anomalies are a genetic primer for cerebral cavernous malformations. Nat Cardiovasc Res. 2022 Mar; 1:246-252.
    View in: PubMed
    Score: 0.053
  37. Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth. J Magn Reson Imaging. 2022 05; 55(5):1440-1449.
    View in: PubMed
    Score: 0.051
  38. Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation. J Clin Invest. 2021 07 01; 131(13).
    View in: PubMed
    Score: 0.050
  39. Cerebral Cavernous Malformation: From Mechanism to Therapy. Circ Res. 2021 06 25; 129(1):195-215.
    View in: PubMed
    Score: 0.050
  40. Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage. J Cereb Blood Flow Metab. 2021 11; 41(11):2944-2956.
    View in: PubMed
    Score: 0.050
  41. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021 06; 594(7862):271-276.
    View in: PubMed
    Score: 0.050
  42. Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials. Neurosurgery. 2021 04 15; 88(5):961-970.
    View in: PubMed
    Score: 0.049
  43. Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. J Exp Med. 2020 10 05; 217(10).
    View in: PubMed
    Score: 0.048
  44. Novel Murine Models of Cerebral Cavernous Malformations. Angiogenesis. 2020 11; 23(4):651-666.
    View in: PubMed
    Score: 0.047
  45. Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. Geroscience. 2020 10; 42(5):1351-1363.
    View in: PubMed
    Score: 0.047
  46. Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nat Commun. 2020 05 27; 11(1):2659.
    View in: PubMed
    Score: 0.047
  47. Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. J Autoimmun. 2020 09; 113:102469.
    View in: PubMed
    Score: 0.046
  48. Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2021 03 01; 134(3):1147-1154.
    View in: PubMed
    Score: 0.046
  49. Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurg. 2020 Apr; 136:7-11.
    View in: PubMed
    Score: 0.045
  50. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
    View in: PubMed
    Score: 0.045
  51. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Sci Transl Med. 2019 11 27; 11(520).
    View in: PubMed
    Score: 0.045
  52. Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites. J Magn Reson Imaging. 2020 04; 51(4):1192-1199.
    View in: PubMed
    Score: 0.044
  53. A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. Transl Stroke Res. 2020 06; 11(3):365-376.
    View in: PubMed
    Score: 0.044
  54. Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathol Commun. 2019 08 19; 7(1):132.
    View in: PubMed
    Score: 0.044
  55. A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasis. Nat Commun. 2019 04 17; 10(1):1791.
    View in: PubMed
    Score: 0.043
  56. Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery. 2019 04 01; 84(4):954-964.
    View in: PubMed
    Score: 0.043
  57. Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
    View in: PubMed
    Score: 0.043
  58. Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood. 2019 01 17; 133(3):193-204.
    View in: PubMed
    Score: 0.042
  59. Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest. 2019 03; 99(3):319-330.
    View in: PubMed
    Score: 0.041
  60. Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. J Exp Med. 2017 Nov 06; 214(11):3331-3346.
    View in: PubMed
    Score: 0.039
  61. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017 05 18; 545(7654):305-310.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.